Phathom Pharmaceuticals Inc
PHATHealthcare|Biotechnology|USA
$12.61
+0.45 (+3.70%)
About
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Stock Price
+30.1%(1Y)
Pipeline Summary
16 total trials8
Phase 1
2
Phase 2
3
Phase 3
2
Phase 4
Completed: 11Active: 3Recruiting: 1Withdrawn: 1
Active Trials (4)
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
NCT06851559Eosinophilic Esophagitis
Phase 2Active
Enrollment: 95 participants
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
NCT06660342Erosive Esophagitis
Recruiting
Enrollment: 728 participants
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2
NCT07224048H. Pylori Infection
Phase 4Active
Enrollment: 75 participants
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1
NCT07224035H Pylori Infection
Phase 4Active
Enrollment: 500 participants
BioScore
5/10
Watchlist
Ownership
Recent Insider Trades
Breedlove Robert CharlesSELL
2025-11-03524 shares @ $13.51
Breedlove Robert CharlesSELL
2025-09-05461 shares @ $12.09
Breedlove Robert CharlesSELL
2025-07-161,692 shares @ $8.36
Topper James NBUY
2025-05-213,780 shares @ $3.86
Topper James NBUY
2025-05-147,420 shares @ $3.3
Recent News
2026-06-23 13:28:20
2026-06-17 11:00:37
Data last updated: Jul 13, 2026, 12:48 PM